{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"664"},{"groupId":"OG001","value":"670"}],"units":"Participants"}],"description":"ORR per IRF was defined as the percentage of participants who achieved CR or partial remission (PR) at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by an IRF. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"OG001","title":"ABVD"}],"paramType":"NUMBER","populationDescription":"The ITT population included all participants randomized to treatment.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of randomized regimen (approximately 1 year)","title":"Overall Response Rate (ORR) Per IRF","type":"SECONDARY","unitOfMeasure":"percentage of participants"}